Hoth Therapeutics (NASDAQ:HOTH) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Hoth Therapeutics (NASDAQ:HOTH) issued its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.01), Zacks reports.

Hoth Therapeutics Stock Performance

Hoth Therapeutics stock traded down $0.05 during trading on Friday, reaching $0.79. The company had a trading volume of 131,667 shares, compared to its average volume of 1,389,142. The firm has a market capitalization of $5.47 million, a PE ratio of -0.59 and a beta of 0.84. The firm’s 50-day simple moving average is $0.92 and its 200 day simple moving average is $0.93. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.73.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HOTH. Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a report on Friday, October 11th. EF Hutton Acquisition Co. I upgraded shares of Hoth Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a research note on Monday, November 4th.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.